News

Video

Camrelizumab Plus Rivoceranib vs Sorafenib as First-Line Therapy for Unresectable Hepatocellular Carcinoma (uHCC): Final Overall Survival Analysis of the Phase 3 CARES-310 Study

Author(s):

Arndt Vogel, MD

This is a final overall survival analysis on the phase 3 CARES-310 study (NCT03764293), a randomized, open-label, international phase 3 trial comparing camrelizumab plus rivoceranib vs sorafenib as first-line therapy for unresectable hepatocellular carcinoma (uHCC).

Related Videos
Chih-Yi Liao, MD
Anthony B. El-Khoueiry, MD
Craig E. Devoe, MD, MS
Ciara Kelly, MBBCh, BAO
Ciara Kelly, MBBCh, BAO
Brigatinib in NF2-Related Schwannomatosis with Progressive Tumors
Ciara Kelly, MBBCh, BAO
Ryan Hood, BA, MD/MPH student, University of Miami Miller School of Medicine
Samuel Cytryn, MD, and David B. Zhen, MD, discuss how immunotherapy plus chemotherapy has improved the durability of outcomes in advanced GI cancers.
Samuel Cytryn, MD, and David B. Zhen, MD, on factors for selecting nivolumab plus chemotherapy or ipilimumab in esophageal squamous cell carcinoma.
Related Content
FDA
September 5th 2024

FDA Awards Orphan Drug Designation to ABD-147 for Neuroendocrine Carcinoma

Stephen Liu, MD; Sara A. Hurvitz, MD, FACP; S. Vincent Rajkumar, MD; Sumanta Kumar Pal, MD, FASCO; Shubham Pant, MD, MBBS
May 23rd 2024

Oncology Experts Preview Top Abstracts From the 2024 ASCO Annual Meeting

Jennifer R. Eads, MD, physician lead of GI Cancer Research and director of the National Clinical Trials Network for Abramson Cancer Center at the University of Pennsylvania; and a professor of clinical medicine (hematology-oncology) at Penn Medicine in the Perelman Center for Advanced Medicine
August 31st 2024

Nivolumab Plus Neoadjuvant Chemoradiation Fails to Enhance pCR Rate in Esophageal/GEJ Adenocarcinoma

Gina Z. D’Amato, MD
February 9th 2023

D'Amato Discusses Research and Resistance Mechanisms in Sarcoma and Gastrointestinal Stromal Tumor

FDA
August 21st 2024

FDA Accepts sBLA for First-Line Nivolumab Plus Ipilimumab in Unresectable HCC

US FDA
August 19th 2024

FDA Awards Orphan Drug Designation to PT217 for Neuroendocrine Carcinoma